期刊
BLOOD
卷 123, 期 23, 页码 3622-3634出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2013-07-516807
关键词
-
类别
资金
- Canadian Institutes of Health Research (CIHR) [GPG-102167]
- Leukemia & Lymphoma Society of Canada
- Canadian Cancer Society
- CIHR
- University of British Columbia
- BC Cancer Agency incentive training award
- CIHR Frederick Banting and Charles Best Canada graduate scholarship
- Leukemia & Lymphoma Society fellowship
- Michael Smith Foundation for Health Research postdoctoral fellowship
Previous studies demonstrated that imatinib mesylate (IM) induces autophagy in chronic myeloid leukemia (CML) and that this process is critical to cell survival upon therapy. However, it is not known if the autophagic process differs at basal levels between CML patients and healthy individuals and if pretreatment CML cells harbor unique autophagy characteristics that could predict patients' clinical outcomes. We now demonstrate that several key autophagy genes are differentially expressed in CD34(+) hematopoietic stem/progenitor cells, with the highest transcript levels detected for ATG4B, and that the transcript and protein expression levels of ATG4 family members, ATG5 and BECLIN-1 are significantly increased in CD34(+) cells from chronic phase CML patients (P < .05). Importantly, ATG4B is differentially expressed in pretreatment CML stem/progenitor cells from subsequent IM responders vs IM non-responders (P < .05). Knockdown of ATG4B suppresses autophagy, impairs the survival of CML stem/progenitor cells and sensitizes them to IM treatment. Moreover, deregulated expression of ATG4B in CD34(+) CML cells inversely correlates with transcript levels of miR-34a, and ATG4B is shown to be a direct target of miR-34a. This study identifies ATG4B as a potential biomarker for predicting therapeutic response in treatment-naive CML stem/progenitor cells and uncovers ATG4B as a possible drug target in these cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据